The Pentagon updated its official war casualty database over the weekend, adding more than 140 wounded service members to the tally from the conflict with Iran. According to the Defense Casualty Analysis System (DCAS), the updated figures show that 18 US troops have been killed and 624 wounded since the US launched its war against Iran on February 28, highlighting an ongoing dispute over troop losses and the War Powers Act.
Defense Casualty Analysis System Introduces New Category
The DCAS database introduced a new casualty category labeled “Overseas Operations” for personnel killed and wounded starting July 7, according to the Pentagon. This shift follows the collapse of a previous ceasefire with Iran and the resumption of near-daily airstrikes beginning on July 6.
Under the updated database, the official toll for the earlier phase of the conflict, known as Operation Epic Fury, stands at 14 service members killed and more than 400 wounded in action. These figures have remained a point of contention after the Pentagon previously reduced the totals from 18 deaths and 482 wounded that had been recorded just days earlier.
Did you know?
The War Powers Act of 1973 requires the president to end military operations within 60 days unless Congress authorizes an extension. The Trump administration has argued that the April ceasefire paused the clock on May 1 for the conflict’s initial period.
War Powers Act Timeline and Legal Challenges
The Trump administration is seeking to classify the renewed military campaign as separate from Operation Epic Fury, a move that would be unprecedented. The separate casualty count beginning on July 7 aligns with the administration’s interpretation that the April ceasefire paused the 60-day clock mandated by the War Powers Act of 1973.
This administrative separation became apparent earlier in the week when the Pentagon’s official online list of service members killed in the ongoing Iran war omitted four soldiers who died during renewed fighting over the weekend. However, their names appeared in a Pentagon press release announcing the formal transfer of their remains back to the United States on Wednesday.
Lawmakers from both parties have challenged the administration’s interpretation of the War Powers Act timeline. Thomas Massie, a Republican House member from Kentucky, criticized the move in an X post, writing: “Let me explain this absurd ruse: The Pentagon is pretending there have been two Iran wars separated by a brief cease-fire.” Massie added that by going more than 90 days without congressional authorization, Pete Hegseth “IS BREAKING THE LAW and must be held accountable.”
Frequently Asked Questions
What is the total US casualty count in the Iran conflict?
According to the updated Pentagon figures combining Operation Epic Fury and the new “Overseas Operations” category, 18 US troops have been killed and 624 wounded since the war began on February 28.
Why did the Pentagon create a new casualty category?
The DCAS database added the “Overseas Operations” category for personnel killed and wounded starting July 7, following the collapse of the ceasefire and the resumption of airstrikes. The administration argues this represents a new phase of operations separate from Operation Epic Fury.
How does the War Powers Act apply to these casualty numbers?
The War Powers Act of 1973 requires the president to end unauthorized military operations within 60 days. The administration contends that the April ceasefire paused this timeline on May 1, a legal interpretation that lawmakers from both parties have challenged.
Join the Discussion
What are your thoughts on the Pentagon’s updated casualty tracking and the application of the War Powers Act? Share your perspective in the comments below, and subscribe to our newsletter for ongoing updates on national security developments.
Keep reading
- Alternative for Germany Surges in Polls
- Malawi Parliament Suspends Probes Amid Crunch Talks Between Speaker and President
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)